Search

Displaying results 3101 - 3110 of 8974 in total
  1. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. … On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Anisotropine methylbromide

    go.drugbank.com/drugs/DB00517
    Approved

    Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

  3. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019. … [A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug

  4. Drug

    Cyclacillin

    go.drugbank.com/drugs/DB01000
    Approved

    A cyclohexylamido analog of penicillanic acid.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine.

  6. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    [A252220, A252225] Spesolimab received recommendations from the EMA's Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and was finally approved … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.

  7. Drug

    Conivaptan

    go.drugbank.com/drugs/DB00872
    Approved

    It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).

  8. Drug

    Gabapentin

    go.drugbank.com/drugs/DB00996
    ApprovedInvestigational

    [L8717] It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain. … It is structurally and functionally related to another GABA derivative, [pregabalin].

  9. Drug

    Lurasidone

    go.drugbank.com/drugs/DB08815
    ApprovedInvestigational

    Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Primidone

    go.drugbank.com/drugs/DB00794
    ApprovedVet approved

    Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. … [L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112]